Sign in
TerminatedPhase 4

Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.

Key facts

Who runs it
I.R.C.C.S. Fondazione Santa Lucia
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
30 people enrolled
Started
31 Jan 2023
Ended
11 Apr 2024
Type of study
Interventional
Treatments tested
  • Ozanimod Oral Capsule
Record updated
15 January 2025
Why it stopped
Sponsor's decision

Who can take part

Age
18 years to 45 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • 1) Diagnosis of MS accordingly to 2017 revised McDonald criteria; 2) Patients candidate to receive Ozanimod therapy (disease characteristics, EDSS, age, lifestyle, disease progression, etc.); 3) Age between 18 and 45 years; 4) EDSS score from 0 to 4; 5) Signature and date of written ICF prior to entering the study

Who cannot take part

  • The presence of any of the following will exclude a patient from study enrolment:; Ongoing immunomodulatory or immunosuppressive treatment; Other autoimmune comorbidities (i.e. antiphospolipid syndrome); Treatment with steroids in the last 30 days before enrollment; Acute inflammatory status not MS related (i.e. bacterial or viral infections) in the previous 30 days; Patients unable to read and understand the documents of the study; Participation in any interventional clinical trials or compassionate use programs; Contraindications and "not-recommendations" reported in SmP

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective interventional study with a 12-month follow-up of patients diagnosed with Multiple Sclerosis. Enrollment includes patients for whom Ozanimod will be prescribed based on regular clinical practice. It is proposed to integrate the measurements obtained using multiple instruments, with the aim of analyzing the immunological landscape, connectivity networks and anatomical traits of neurodegeneration.

Read full original descriptionShow less

Patients will return for imaging and noninvasive electrophysiological studies 3, 6, and 12 months after initiation of therapy. On the same day, blood samples will be taken and immunological and biochemical tests will be performed.

The group in the trial

  • PatientTreatment being tested

    Treatment: Ozanimod Oral Capsule

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multidimensional Integrated Assessment of Neurological and Immunological Patterns to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.
Record updated
15 January 2025